Ostem Implant Reports Q1 Operating Profit of 51.2 Billion KRW... "All-Time High"

[Asia Economy Reporter Jang Hyowon] Ostem Implant (CEO Eom Taegwan), the world's No. 1 implant sales company, announced its preliminary earnings for the first quarter of this year on the 26th.

[Image source=Yonhap News]

Ostem Implant's sales in the first quarter of this year reached 234.1 billion KRW, an increase of more than 36% compared to the same period last year, and operating profit recorded 51.2 billion KRW, more than doubling compared to the same period last year. Sales were the highest ever for a first quarter, and operating profit surpassed 50 billion KRW for the first time in a quarter.

An Ostem Implant official stated, "The first quarter saw expanded growth due to increased sales from overseas subsidiaries, continued strong implant sales, and growth in the digital dentistry product line."

In particular, the growth of overseas subsidiaries was remarkable. Ostem Implant's overseas sales in the first quarter of this year were 168 billion KRW, a 58% increase compared to the same period last year, and this figure also increased compared to the fourth quarter of last year, which had the greatest year-end effect.

Major subsidiaries in China, Russia, and the United States showed noticeable growth. China's first-quarter sales grew 56% year-on-year, Russia's first-quarter sales increased by 59%, and the U.S. first-quarter sales grew by 76% compared to the same period last year. In the U.S., the implant brand HiOssen under the U.S. subsidiary gradually strengthened its position, driving profit growth.

Ostem Implant has set its sales target for this year at 1 trillion KRW and operating profit target at 170 billion KRW. A company representative said, "Riding on the strong first-quarter performance, we will continue the high-growth trend. We will accelerate global expansion based on core technologies and products such as implants, digital dentistry, and orthodontics, while also considering global M&A."

Ostem Implant is preparing to launch various new implant-related products. In the digital field, a large number of new products such as updated versions of CAD software, oral scanners, milling machines, and 3D printers are scheduled for release. In the first quarter of this year, the company officially entered the orthodontics field by launching the clear aligner 'MagicAlign' and is accelerating preparations for overseas market entry in China, Japan, Australia, and other countries.

The global network is also expanding further. Currently operating 30 overseas subsidiaries in 26 countries, Ostem Implant plans to enter more than five additional countries including Spain this year. Following the sales growth trend, the company is also expanding its production facility in Philadelphia, USA. By the second half of this year, it will have a 1,396-pyeong (approximately 4,610 square meters) production facility, increasing annual production by about 58% compared to the previous year. Additionally, the company plans to further increase overseas market share through product diversification, operating direct sales organizations for localized services, and clinical education for dentists.

Eom Taegwan, CEO of Ostem Implant, said, "Although we experienced temporary profit damage last year due to an employee embezzlement issue, we made every effort to normalize the business, resulting in high performance in the first quarter and continuing the high-growth trend. Thanks to the steep performance growth of overseas subsidiaries, we will not only achieve 1 trillion KRW in sales this year but also actively consider M&A in various fields that can create synergy with existing businesses, taking a step closer to achieving the vision of becoming the world's No. 1 implant company by 2026."

This content was produced with the assistance of AI translation services.